Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

Cubist Pharmaceuticals

This page shows the latest Cubist Pharmaceuticals news and features for those working in and with pharma, biotech and healthcare.

Merck prepares filings for Clostridium antibody

Merck prepares filings for Clostridium antibody

Merck bolstered its anti-infectives pipeline last year with the $8.4bn acquisition of Cubist Pharmaceuticals, which added a range of antibiotics including recently-approved Sivextro (tedizolid phosphate) and Zerbaxa

Latest news

  • Merck hopes for another Keytruda with new immunotherapy deal Merck hopes for another Keytruda with new immunotherapy deal

    Merck also said it expects to see an increase in overall revenue from its recent $8.4bn purchase of Cubist Pharmaceuticals, the maker of blockbuster antibiotic Cubicin, which made $480m.

  • Actavis gets FDA nod for new antibiotic Actavis gets FDA nod for new antibiotic

    Avycaz' closest rival among these is Cubist Pharmaceuticals' Zerbaxa (ceftolozane/tazobactam) - which has been tipped as a $1bn-plus product - while the others are Cubist's Sivextro (tedizolid), Durata/Actavis' Dalvance

  • Antibiotics among 7 new drugs backed by EMA Antibiotics among 7 new drugs backed by EMA

    Antibiotics among 7 new drugs backed by EMA. The Medicines Company’ s Orbactiv and Cubist’ s Sivextro set for European approval. ... Both The Medicines Company's Orbactiv (oritavancin) and Cubist's Sivextro (tedizolid phosphate) were among seven new

  • FDA backs Cubist's antibiotic Zerbaxa FDA backs Cubist's antibiotic Zerbaxa

    FDA backs Cubist's antibiotic Zerbaxa. Combination cephalosporin and beta lactamase inhibitor wins US approval. ... Cubist Pharmaceuticals has rounded off a busy few months with its second approval for a new antibiotic, this time getting FDA approval for

  • Merck stumps up $375m for cancer firm OncoEthix Merck stumps up $375m for cancer firm OncoEthix

    Merck stumps up $375m for cancer firm OncoEthix. Follows $8.4bn deal to buy Cubist. ... tumours. The acquisition is Merck's second this month after it agreed an $8.4bn takeover deal with anti-infectives specialist Cubist Pharmaceuticals.

More from news
Approximately 10 fully matching, plus 13 partially matching documents found.

Latest Intelligence

  • Curbing the rise of drug resistance Curbing the rise of drug resistance

    Rekindling anti-microbial innovation . Although doctors and veterinarians (and, indirectly, patients) have a responsibility to cut back the volume of antibiotic prescriptions, it is the pharmaceuticals sector that holds the greatest ... The KPMG report

  • Cubist: Meeting the challenge in antibiotics Cubist: Meeting the challenge in antibiotics

    Cubist: Meeting the challenge in antibiotics. Patrick Vink on Cubist Pharmaceuticals’ ambitions in anti-infectives, which have attracted the attention of Merck &Co. ... Cubist expansion. One company that has remained in the field despite these

  • Deal Watch table for July 2013 Deal Watch table for July 2013

    8, 600. Trius Therapeutics / Cubist Pharmaceuticals. Acquisition. Antibiotic pipeline inc TR-701 (tedizolid phosphate, p3). ... 815. Optimer Pharmaceuticals / Cubist Pharmaceuticals. Acquisition. Antibiotic pipeline based on Dificid (fidaxomicin) for

  • Pharma deals during July 2013 Pharma deals during July 2013

    Whilst the Elan and Perrigo deal creates a diversified business, several companies, such as Cubist, Ipsen and Spectrum Pharmaceuticals, focused on acquiring assets to bolster their core business areas in antibiotics, ... On the same day, Cubist announced

  • Pharma deals during March 2013 Pharma deals during March 2013

    Paying $25m upfront in cash, Cubist Pharmaceuticals is buying the rights to ceftolozane in certain Asia-Pacific and Middle East territories from Astellas. ... Astellas Pharma/ Cubist Pharmaceuticals ††. Acquisition of rights. Ceftolozane for

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest appointments

  • Constellation Pharmaceuticals appoints Emma Reeve as CFO Constellation Pharmaceuticals appoints Emma Reeve as CFO

    Constellation Pharmaceuticals appoints Emma Reeve as CFO. The US firm has also recruited Brad Prosek to corporate development role. ... Prior to that he spent ten years at Cubist Pharmaceuticals, Biogen and Covance.

  • Nabriva Therapeutics appoints new chief commercial officer Nabriva Therapeutics appoints new chief commercial officer

    Prior to serving MSD as its acting vice president, global brand leader anti-infective portfolio, he was vice president, international marketing for the anti-infectives portfolio at Cubist Pharmaceuticals.

  • Cubist’s Dr Lorianne Masuoka jumps ship to InVivo Cubist’s Dr Lorianne Masuoka jumps ship to InVivo

    InVivo Therapeutics has appointed former Cubist executive team leader Dr Lorianne Masuoka as its new chief medical officer. ... She takes over from the interim CMO, Lou Vaickus. Prior to joining the InVivo team, Dr Masuoka served as senior VP and CMO at

  • Cubist picks Robert Perez as its new CEO Cubist picks Robert Perez as its new CEO

    Cubist picks Robert Perez as its new CEO. He replaces Michael Bonney who will continue as chair. ... Antibiotic specialist Cubist Pharmaceuticals has announced that CEO Michael Bonney will step down from his position at the end of this year to be

More from appointments
Approximately 1 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Streaming Well

Streaming Well is a healthcare focused, award-winning video production company which operates in the US and Europe....

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Quick links

Infographics

Multimedia